Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

2.

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.

Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.

Clin Cancer Res. 2004 Jul 1;10(13):4398-405.

3.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.

Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review.

PMID:
16787142
4.

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.

Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T.

J Clin Endocrinol Metab. 2001 Dec;86(12):5729-36.

PMID:
11739429
5.

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.

Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D.

Expert Opin Investig Drugs. 2002 Feb;11(2):283-93. Review.

PMID:
11829717
6.

Chemotherapy for hormone-refractory prostate cancer.

Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247. Review.

PMID:
17054249
7.

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.

Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M.

Anticancer Res. 2006 Sep-Oct;26(5B):3693-700.

8.

Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.

González-Barcena D, Schally AV, Vadillo-Buenfil M, Cortez-Morales A, Hernández L V, Cardenas-Cornejo I, Comaru-Schally AM.

Prostate. 2003 Aug 1;56(3):183-91.

PMID:
12772187
9.

Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.

BJU Int. 2007 Jul;100 Suppl 2:60-2. Review. No abstract available.

10.

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).

Mitsogiannis IC, Skolarikos A, Deliveliotis C.

Expert Opin Pharmacother. 2009 Feb;10(3):493-501. doi: 10.1517/14656560802694689 . Review.

PMID:
19191684
11.

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.

Urology. 2003 Jul;62(1):99-104.

PMID:
12837431
12.

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.

Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL.

Cancer. 1995 Jul 1;76(1):96-100.

13.
14.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
15.

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2.

PMID:
20884247
17.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
18.

Bisphosphonates for advanced prostate cancer.

Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006250. Review.

PMID:
17054286
19.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
20.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080

Supplemental Content

Support Center